Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease

Apr 4

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease - Lin et al. 2019

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease

Publication Date: 2019.10.04

Authors: Lin CH, Liu HC, Yang SY, Yang KC, Wu CC and Chiu MJ

Journal: J. Clin. Med. 2019 Oct 3.

Citation

Lin CH, Liu HC, Yang SY, Yang KC, Wu CC and Chiu MJ, "Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson's Disease", J. Clin. Med. 2019 Oct 3.

Yiran Gan

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease

Citation

Article Link

Associations between Plasma Biomarkers and Cognition in Patients with Alzheimer’s Disease and Amnestic Mild Cognitive Impairment: A Cross-Sectional and Longitudinal Study

Plasma Aβ42 and Total Tau Predict Cognitive Decline in Amnestic Mild Cognitive Impairment